Vital Signs: Carbapenem-Resistant Enterobacteriaceae

Background Enterobacteriaceae are a family of bacteria that commonly cause infections in health-care settings as well as in the community. Among Enterobacteriaceae, resistance to broad-spectrum carbapenem antimicrobials has been uncommon. Over the past decade, however, carbapenem-resistant Enterobacteriaceae (CRE) have been recognized in health-care settings as a cause of difficult-to-treat infections associated with high mortality. Methods The percentage of acute-care hospitals reporting at least one CRE from health-care–associated infections (HAIs) in 2012 was estimated using data submitted to the National Healthcare Safety Network (NHSN) in 2012. The proportion of Enterobacteriaceae infections that were CRE was calculated using two surveillance systems: 1) the National Nosocomial Infection Surveillance system (NNIS) and NHSN (for 2001 and 2011, respectively) and 2) the Surveillance Network–USA (TSN) (for 2001 and 2010). Characteristics of CRE culture-positive episodes were determined using data collected as part of a population-based CRE surveillance project conducted by the Emerging Infections Program (EIP) in three states. Results In 2012, 4.6% of acute-care hospitals reported at least one CRE HAI (short-stay hospitals, 3.9%; long-term acute-care hospitals, 17.8%). The proportion of Enterobacteriaceae that were CRE increased from 1.2% in 2001 to 4.2% in 2011 in NNIS/NHSN and from 0% in 2001 to 1.4% in 2010 in TSN; most of the increase was observed in Klebsiella species (from 1.6% to 10.4% in NNIS/NHSN). In the EIP surveillance, 92% of CRE episodes occurred in patients with substantial health-care exposures. Conclusions Carbapenem resistance among common Enterobacteriaceae has increased over the past decade; most CRE are associated with health-care exposures. Implications for Public Health Interventions exist that could slow the dissemination of CRE. Health departments are well positioned to play a leading role in prevention efforts by assisting with surveillance, situational awareness, and coordinating prevention efforts.

[1]  V. B. D. De Rochars,et al.  Outbreak of Carbapenem-Resistant Enterobacteriaceae at a Long-Term Acute Care Hospital: Sustained Reductions in Transmission through Active Surveillance and Targeted Interventions , 2012, Infection Control & Hospital Epidemiology.

[2]  C. van der Werken,et al.  A Dutch Approach to Methicillin-Resistant Staphylococcus aureus , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  R. Gaynes,et al.  Resistance to Imipenem Among Selected Gram-Negative Bacilli in the United States , 1992, Infection Control & Hospital Epidemiology.

[4]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[5]  David L. Smith,et al.  Community-associated Methicillin-Resistant Staphylococcus aureus in Outpatients, United States, 1999–2006 , 2009, Emerging infectious diseases.

[6]  Arjun Srinivasan,et al.  Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010 , 2013, Infection Control & Hospital Epidemiology.

[7]  K. Bush,et al.  Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[8]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[9]  J. Heitman.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2000 .

[10]  J. Jernigan.  Control of vancomycin-resistant Enterococcus in health care facilities in a region , 2002, Current infectious disease reports.

[11]  R. Weinstein,et al.  Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  W. Trick,et al.  Control of vancomycin-resistant enterococcus in health care facilities in a region. , 2001, The New England journal of medicine.

[13]  Ph.D. Joseph Heitman M.D.,et al.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2004, Mycopathologia.

[14]  Y. Carmeli,et al.  Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital , 2007, Antimicrobial Agents and Chemotherapy.

[15]  R. Moreau,et al.  10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum β-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. , 2013, The Journal of antimicrobial chemotherapy.

[16]  Y. Carmeli,et al.  Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Augenbraun,et al.  Success of an Infection Control Program to Reduce the Spread of Carbapenem-Resistant Klebsiella pneumoniae , 2009, Infection Control & Hospital Epidemiology.

[18]  D. Snydman,et al.  Carbapenem-Resistant Enterobacteriaceae: A Statewide Survey of Detection in Massachusetts Hospitals , 2012, Infection Control & Hospital Epidemiology.

[19]  M. Bassetti,et al.  Will new antimicrobials overcome resistance among Gram-negatives? , 2011, Expert review of anti-infective therapy.

[20]  J. Rahimian,et al.  Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Gopi Patel,et al.  Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.